Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

The rationale for antidepressants in the treatment of schizophrenia: A modern view on the problem in the context of evidence-based medicine

https://doi.org/10.14412/2074-2711-2016-1-71-81

Full Text:

Abstract

The paper discusses whether antidepressant treatment is rational in schizophrenics. It analyzes the results from trials evaluating the efficiency of the therapy in patients with depressive, negative, or obsessive-phobic symptoms. The validity of results of these trials is assessed. The results of demonstrative trials of the efficiency of therapy with different representatives of antidepressants (selective serotonin reuptake inhibitors) in the above patient groups are given separately and compared with the data obtained in observational studies. Emphasis is placed on the criticism of shortages of procedures and results of demonstrative trials conducted in foreign countries. Prospects for further trials evaluating the efficiency of antidepressant therapy for schizophrenia are depicted.

About the Authors

D. S. Danilov
S.S. Korsakov Clinic of Psychiatry, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia 11, Rossolimo St., Build. 9, Moscow 119021
Russian Federation


D. O. Magomedova
Department of Psychiatry and Narcology, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia 11, Rossolimo St., Build. 9, Moscow 119021
Russian Federation


M. E. Matsneva
Department of Psychiatry and Narcology, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia 11, Rossolimo St., Build. 9, Moscow 119021
Russian Federation


References

1. Андрусенко МП, Морозова МА. Комбинированное использование антидепрессантов и нейролептиков при аффективных расстройствах и шизофрении: показания к назначению, побочные эффекты и осложнения. Психиатрия и психофармакотерапия. 2001;3(1):4-9. [Andrusenko MP, Morozova MA. The combined use of antidepressants and antipsychotics in mood disorders and schizophrenia: indications for use, side effects and complications. Psikhiatriya i psikhofarmakoterapiya. 2001;3(1):4-9. (In Russ.)].

2. Siris SG, Addington D, Azorin J, et al. Depression in schizophrenia: recognition and management in the USA. Schizophr Res. 2001 Mar 1;47(2-3):185-97.

3. Acquaviva E, Gasquet I, Falissard B. Psychotropic combination in schizophrenia. Eur J Clin Pharmacol. 2005 Dec;61(11):855-61. Epub 2005 Nov 8.

4. Вовин РЯ, Свердлов ЛС. Ремиссии при приступообразной шизофрении. Медикаментозная профилактика и купирование рецидивов (методические рекомендации). Ленинград: ЛНИПНИ им. В.М. Бехтерева; 1985. 20 c. [Vovin RYa, Sverdlov LS. Remissii pri pristupoobraznoi shizofrenii. Medikamentoznaya profilaktika i kupirovanie retsidivov (metodicheskie rekomendatsii) [Remission of paroxysmal schizophrenia. Pharmacological prevention and relief of recurrence (guidelines)]. Leningrad: LNIPNI im. V.M. Bekhtereva; 1985. 20 p.]

5. Смулевич АБ, Румянцева ГМ, Завидовская ГИ и др. Депрессивные фазы в рамках шизофрении. В кн.: Штернберг ЭЯ, Смулевич АБ, редакторы. Депрессии. Вопросы клиники, психопатологии, терапии. Москва–Базель: МЗ СССР, СИБА-ГЕЙГИ, Институт Психиатрии АМН СССР; 1970. С. 29-39. [Smulevich AB, Rumyantseva GM, Zavidovskaya GI, et al. Depressive phases in the context of schizophrenia. In: Shternberg EYa, Smulevich AB, editors. Depressii. Voprosy kliniki, psikhopatologii, terapii [Depression. Questions of clinics, psychopathology, therapy]. Moscow – Basel: The USSR Ministry of health, CIBA-GEIGY, Institute of Psychiatry of AMS USSR; 1970. P. 29-39.]

6. Дробижев МЮ. Депрессивные состояния при вялотекущей шизофрении с преобладанием негативных расстройств. Автореф. дисс. канд. мед. наук. Москва; 1991. 23 с. [Drobizhev MYu. Depression in low schizophrenia with predominance of negative disorders. Autoref. diss. cand. med. sci. Moscow; 1991. 23 p.]

7. Шумская КН. Постшизофренические депрессии (психопатологические особенности и вопросы типологии, клинические подходы, терапевтические особенности). Автореф. дисс. канд. мед. наук. Москва; 1999. 21 с. [Shumskaya KN. Postschizophrenic depressions (psychopathological features and typology, clinical approaches, therapeutic features). Autoref. diss. cand. med. sci. Moscow; 1999. 21 p.]

8. Кинкулькина МА. Депрессии при шизофрении и алкоголизме. Автореф. дисс. докт. мед. наук. Москва; 2008. 48 с. [ Kinkul'kina MA. Depression in schizophrenia and alcoholism. Autoref. diss. doct. med. sci. Moscow; 2008. 48 p.]

9. Prusoff BA, Williams DH, Weissman MM, Astrachan BM. Treatment of secondary depression in schizophrenia. A double-blind, placebocontrolled trial of amitriptyline added to perphenazine. Arch Gen Psychiatry. 1979 May;36(5):569-75.

10. Plasky P. Antidepressant usage in schizophrenia. Schizophr Bull. 1991;17(4):649-57.

11. Kasckow J, Lanouette N, Patterson T, et al. Treatment of subsyndromal depressive symptoms in middle-age and older adults with schizophrenia: effect on functioning. Int J Geriatr Psychiatry. 2010 Feb;25(2):183-90. doi: 10.1002/gps.2318.

12. Портнов ВВ. Депрессивно-параноидные состояния при шизофрении (клинико-психопатологическая дифференциация, вопросы прогноза и лечения). Автореф. дисс. канд. мед. наук. Москва; 2007. 22 с. [Portnov VV. Depressive-paranoid states in schizophrenia (clinical and psychopathological differentiation, prognosis and treatment). Autoref. diss. cand. med. sci. Moscow; 2007. 22 p.]

13. Вдовенко АМ. Юношеский эндогенный приступообразный психоз, манифестирующий приступом депрессивно-бредовой структуры (клинико-психопатологическое и клинико-катамнестическое исследование). Дисс. канд. мед. наук. Москва; 2012. 225 с. [Vdovenko AM. Paroxysmal juvenile endogenous psychosis, seizure manifest depressivedelusional patterns (clinical-psychopathological and clinical follow-up study). Diss. cand. med. sci. Moscow; 2012. 225 p.]

14. Moller HJ, von Zerssen D. Depression in schizophrenia. In: Burrows GD, Norman TR, Rubinstein G, editors. Handbook of studies on schizophrenia. Part 1. Amsterdam: Elsevier Science Publishers; 1986. P. 183-91.

15. Dufresne RL, Kass DJ, Becker RE. Bupropion and thiothixene versus placebo and thiothixene in the treatment of depression in schizophrenia. Drug Development Research. 1988;12(3-4):259-66.

16. Kramer MS, Vogel WH, DiJohnson C, et al. Antidepressants in 'depressed' schizophrenic inpatients. A controlled trial. Arch Gen Psychiatry. 1989 Oct;46(10):922-8.

17. Zisook S, McAdams LA, Kuck J, et al. Depressive symptoms in schizophrenia. Am J Psychiatry. 1999 Nov;156(11):1736-43.

18. Барроус ГД, Норман ТР. Аффективные расстройства при шизофрении. В кн.: Энсилл РДж, Холлидей С, Хигенботтэм Дж, редакторы. Шизофрения. Изучение спектра психозов. Москва: Медицина; 2001. С. 223-32. [Barrous GD, Norman TR. Affective disorders in schizophrenia. In: Ensill RDzh, Khollidei S, Khigenbottem Dzh, editors. Shizofreniya. Izuchenie spektra psikhozov [Schizophrenia. The study of the spectrum of psychoses]. Moscow: Meditsina; 2001. P. 223-32.]

19. Tapp A, Kilzieh N, Wood AE, et al. Depression in patients with schizophrenia during an acute psychotic episode. Compr Psychiatry. 2001 Jul-Aug;42(4):314-8.

20. Whitehead C, Moss S, Cardno A, Lewis G. Antidepressants for people with both schizophrenia and depression. Cochrane Database Syst Rev. 2002;(2):CD002305.

21. Micallef J, Fakra E, Blin O. Use of antidepressant drugs in schizophrenic patients with depression (article in French). Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9.

22. Kishi T, Hirota T, Iwata N. Add-on fluvoxamine treatment for schizophrenia: an updated meta-analysis of randomized controlled trials. Eur Arch Psychiatry Clin Neurosci. 2013 Dec;263(8): 633-41. doi: 10.1007/s00406-013-0406-3. Epub 2013 Apr 21.

23. Kishi T, Iwata N. Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia. Int J Neuropsychopharmacol. 2014 Feb;17(2):343-54. doi: 10.1017/ S1461145713000667. Epub 2013 Jul 3.

24. Уильямс Р. Депрессия у больных шизофренией. В кн.: Энсилл РДж, Холлидей С, Хигенботтэм Дж, редакторы. Шизофрения. Изучение спектра психозов. Москва: Медицина; 2001. С. 247-62. [Uil'yams R. Depression in patients with schizophrenia. In: Ensill RDzh, Khollidei S, Khigenbottem Dzh, editors. Shizofreniya. Izuchenie spektra psikhozov [Schizophrenia. The study of the spectrum of psychoses]. Moscow: Meditsina; 2001. P. 247-62.]

25. Feldman PE. The treatment of anergic schizophrenia with imipramine. J Clin Exp Psychopathol Q Rev Psychiatry Neurol. 1959 Jul-Sep;20:235-42.

26. Feldman PE. Treatment of anergic schizophrenia with nialamide. Dis Nerv Syst. 1959 Aug;20(Suppl):41-6.

27. Авруцкий ГЯ, Гурович ИЯ, Громова ВВ. Фармакотерапия психических заболеваний. Москва: Медицина; 1974. 472 с. [Avrutskii GYa, Gurovich IYa, Gromova VV. Farmakoterapiya psikhicheskikh zabolevanii [Pharmacotherapy of mental disorders]. Moscow: Meditsina; 1974. 472 p.]

28. Смулевич АБ. Малопрогредиентная шизофрения и пограничные состояния. Москва: Медицина; 1987. 240 с. [Smulevich AB. Maloprogredientnaya shizofreniya i pogranichnye sostoyaniya [Small-progredient schizophrenia and borderline states]. Moscow: Meditsina; 1987. 240 p.]

29. Авруцкий ГЯ, Недува АА. Лечение психически больных. Москва: Медицина; 1988. 528 с. [Avrutskii GYa, Neduva AA. Lechenie psikhicheski bol'nykh [The treatment of the mentally ill]. Moscow: Meditsina; 1988. 528 p.]

30. Воробьев ВЮ. Шизофренический дефект (на модели шизофрении, протекающей с преобладанием негативных расстройств). Дисс. докт. мед. наук. Москва; 1988. 128 с. [Vorob'ev VYu. Schizophrenic defect (on the model of schizophrenia, occurring with a predominance of negative disorders). Diss. doct. med. sci. Moscow; 1988. 128 p.]

31. Sepehry AA, Potvin S, Elie R, et al. Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis. J Clin Psychiatry. 2007 Apr;68(4):604-10.

32. Mico U, Bruno A, Pandolfo G, et al. Duloxetine as adjunctive treatment to clozapine in patients with schizophrenia: a randomized, placebo-controlled trial. Int Clin Psychopharmacol. 2011 Nov;26(6):303-10. doi: 10.1097/YIC.0b013e32834bbc0d.

33. Rummel-Kluge C, Kissling W, Leucht S. Antidepressants for the negative symptoms of schizophrenia. Cochrane Database Syst Rev. 2006 Jul 19;(3):CD005581.

34. Yamagami S, Soejima K. Effect of maprotiline combined with conventional neuroleptics against negative symptoms of chronic schizophrenia. Drugs Exp Clin Res. 1989;15(4):171-6.

35. Waehrens J, Gerlach J. Antidepressant drugs in anergic schizophrenia. A double-blind crossover study with maprotiline and placebo. Acta Psychiatr Scand. 1980 May;61(5):438-44.

36. Silver H, Shmugliakov N. Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study. J Clin Psychopharmacol. 1998 Jun;18(3):208-11.

37. Singh SP, Singh V, Kar N, et al. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br J Psychiatry. 2010 Sep;197(3):174-9. doi: 10.1192/bjp.bp.109.067710.

38. Lindenmayer JP, Kay SR. Depression, affect and negative symptoms in schizophrenia. Br J Psychiatry Suppl. 1989 Nov;(7):108-14.

39. Vernon JA, Grudnikoff E, Seidman AJ, et al. Antidepressants for cognitive impairment in schizophrenia – a systematic review and meta-analysis. Schizophr Res. 2014 Nov;159 (2-3):385-94. doi: 10.1016/j.schres.2014.08.015. Epub 2014 Sep 18.

40. Гиндикин ВЯ, Гурьева ВА. Личностная патология. Москва: Триада-Х; 1999. 266 с. [Gindikin VYa, Gur'eva VA. Lichnostnaya patologiya [Personality pathology]. Moscow: Triada-X; 1999. 266 p.]

41. Смулевич АБ. Лечение вялотекущей шизофрении. В кн.: Тиганов АС, редактор. Руководство по психиатрии, Том 1. Москва: Медицина; 1999. С. 537-9. [Smulevich AB. Treatment of low schizophrenia. In: Tiganov AS, editor. Rukovodstvo po psikhiatrii [A manual on psychiatry] Vol. 1. Moscow: Meditsina; 1999. P. 537-9.]

42. Poyurovsky M, Hermesh H, Weizman A. Fluvoxamine treatment in clozapine-induced obsessive-compulsive symptoms in schizophrenic patients. Clin Neuropharmacol. 1996 Aug;19(4):305-13.

43. Gonzalez PB, Facorro CB, Herrero SM, et al. Obsessive-compulsive symptoms in schizophrenia: remission with anti-obsessive treatment (article in Spanish). Actas Luso Esp Neurol Psiquiatr Cienc Afines. 1998 May-Jun; 26(3):201-3.

44. Poyurovsky M, Kurs R, Weizman A. Olanzapine-sertraline combination in schizophrenia with obsessive-compulsive disorder. J Clin Psychiatry. 2003 May;64(5):611.

45. Zohar J, Kaplan Z, Benjamin J. Clomipramine treatment of obsessive compulsive symptomatology in schizophrenic patients.J Clin Psychiatry. 1993 Oct;54(10):385-8.

46. Poyurovsky M, Isakov V, Hromnikov S, et al. Fluvoxamine treatment of obsessive-compulsive symptoms in schizophrenic patients: an add-on open study. Int Clin Psychopharmacol. 1999 Mar;14(2):95-100.

47. Reznik I, Sirota P. An open study of fluvoxamine augmentation of neuroleptics in schizophrenia with obsessive and compulsive symptoms. Clin Neuropharmacol. 2000 May- Jun;23(3):157-60.

48. Dwivedi S, Pavuluri M, Heidenreich J, et al. Response to fluvoxamine augmentation for obsessive and compulsive symptoms in schizophrenia. J Child Adolesc Psychopharmacol. 2002 Spring;12(1):69-70.

49. Sayeed Khan MN, Arshad N, Ullah N. Treatment outcome of schizophrenia co-morbid with obsessive-compulsive disorder. J Coll Physicians Surg Pak. 2004 Apr;14(4):234-6.

50. Stryjer R, Dambinsky Y, Timinsky I, et al. Escitalopram in the treatment of patients with schizophrenia and obsessive-compulsive disorder: an open-label, prospective study. Int Clin Psychopharmacol. 2013 Mar;28(2):96-8. doi: 10.1097/YIC.0b013e32835bd24e.

51. Berman I, Sapers BL, Chang HH, et al. Treatment of obsessive-compulsive symptoms in schizophrenic patients with clomipramine. J Clin Psychopharmacol. 1995 Jun;15(3):206-10.

52. Raj M, Farooq S. Interventions for obsessive compulsive symptoms in people with schizophrenia. Cochrane Database Syst Rev. 2005;(2). pii: CD005236.

53. Kim SW, Shin IS, Kim JM, et al. The 5-HT2 receptor profiles of antipsychotics in the pathogenesis of obsessive-compulsive symptoms in schizophrenia. Clin Neuropharmacol. 2009 Jul-Aug;32(4):224-6. doi: 10.1097/WNF.0b013e318184fafd.

54. Schirmbeck F, Esslinger C, Rausch F, et al. Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia. Psychol Med. 2011 Nov;41(11): 2361-73. doi: 10.1017/S0033291711000419. Epub 2011 Apr 5.

55. Bark N, Lindenmayer JP. Ineffectiveness of clomipramine for obsessive-compulsive symptoms in a patient with schizophrenia. Am J Psychiatry. 1992 Jan;149(1):136-7.

56. Buchanan RW, Kirkpatrick B, Bryant N, et al. Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. Am J Psychiatry. 1996 Dec;153(12):1625-7.

57. Колюцкая ЕВ. Обсессивно-фобические расстройства при шизофрении и нарушениях шизофренического спектра. Дисс. докт. мед. наук. Москва; 2001. 211 с. [Kolyutskaya EV. Obsessive-phobic disorders in schizophrenia and schizophrenia spectrum disorders. Diss. doct. med. sci. Moscow; 2001. 211 p.]

58. Дороженок ИЮ. Обсессии контрастного содержания (клиника, типология, терапия). Дисс. канд. мед. наук. Москва; 2008. 168 с. [Dorozhenok IYu. Obsessions with contrast content (clinics, typology, therapy). Diss. cand. med. sci. Moscow; 2008. 168 p.]

59. Железнова МВ. Двигательные навязчивости при неврозоподобной шизофрении (клиника, типология, терапия). Дисс. канд. мед. наук. Москва; 2008. 153 с. [Zheleznova MV. Motor obsession with neurosis-like schizophrenia (symptoms, types, treatment). Diss. cand. med. sci. Moscow; 2008. 168 p.]

60. Стась СЮ. Обсессии контрастного содержания при вялотекущей шизофрении (клиника, типология, терапия). Диссертация кандидата медицинских наук. Москва; 2008. 168 с. [Stas' SYu. Obsessions with contrast content in low schizophrenia (symptoms, types, treatment). Diss. cand. med. sci. Moscow; 2008. 168 p.]

61. Павлова ЛК. Ипохондрические ремиссии при шизофрении (клиника, типологическая дифференциация, терапия). Дисс. канд. мед. наук. Москва; 2009. 166 с.

62. [Pavlova LK. Hypochondriacal remissions in schizophrenia (clinical, typological differentiation, therapy). Diss. cand. med. sci. Moscow; 2009. 166 p.]

63. Загороднова ЮБ. Коморбидные обсессивно-компульсивные и галлюцинаторно-бредовые расстройства при вялотекущей шизофрении (клиника, терапия). Дисс. канд. мед. наук. Москва; 2010. 157 с. [Zagorodnova YuB. Comorbid obsessive-compulsive

64. and hallucinatory-delusional disorders in low schizophrenia (clinic, therapy). Diss. cand. med. sci. Moscow; 2010. 157 p.]

65. Мазо ГЭ, Горбачев СЕ. Депрессия при шизофрении: опыт и подходы практических врачей к диагностике и терапии. Социальная и клиническая психиатрия. 2009;19(4):5-14. [Mazo GE, Gorbachev SE. Depression in schizophrenia: the experience and approaches of the practitioners to diagnosis and therapy. Sotsial'naya i klinicheskaya psikhiatriya. 2009;19(4):5-14. (In Russ.)].

66. Silver H, Nassar A. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study. Biol Psychiatry. 1992 Apr 1;31(7):698-704.

67. Silver H, Barash I, Aharon N, et al. Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study. Int Clin Psychopharmacol. 2000 Sep;15(5):257-61.

68. Niitsu T, Fujisaki M, Shiina A, et al. A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: a preliminary study. J Clin Psychopharmacol. 2012 Oct;32(5):593-601. doi: 10.1097/JCP.0b013e3182664cfc.

69. Spina E, de Domenico P, Ruello C, et al. Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. Int Clin Psychopharmacol. 1994 Winter;9(4):281-5.

70. Goff DC, Midha KK, Sarid-Segal O, et al. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology (Berl). 1995 Feb;117(4):417-23.

71. Arango C, Kirkpatrick B, Buchanan RW. Fluoxetine as an adjunct to conventional antipsychotic treatment of schizophrenia patients with residual symptoms. J Nerv Ment Dis. 2000 Jan;188(1):50-3.

72. Vartiainen H, Tiihonen J, Putkonen A, et al. Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia. Acta Psychiatr Scand. 1995 May;91(5):348-51.

73. Salokangas RK, Saarijä rvi S, Taiminen T, et al. Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study. Acta Psychiatr Scand. 1996 Sep;94(3):175-80.

74. Friedman JI, Ocampo R, Elbaz Z, et al. The effect of citalopram adjunctive treatment added to atypical antipsychotic medications for cognitive performance in patients with schizophrenia. J Clin Psychopharmacol. 2005 Jun;25(3):237-42.

75. Zisook S, Kasckow JW, Golshan S, et al. Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: a randomized controlled trial. J Clin Psychiatry. 2009 Apr;70(4):562-71. Epub 2008 Dec 16.

76. Zisook S, Kasckow JW, Lanouette NM, et al. Augmentation with citalopram for suicidal ideation in middle-aged and older outpatients with schizophrenia and schizoaffective disorder who have subthreshold depressive symptoms: a randomized controlled trial. J Clin Psychiatry. 2010 Jul;71(7):915-22. doi: 10.4088/JCP.09m05699gre. Epub 2010 Mar 9.

77. Hinkelmann K, Yassouridis A, Kellner M, et al. No effects of antidepressants on negative symptoms in schizophrenia. J Clin Psychopharmacol. 2013 Oct;33(5):686-90. doi: 10.1097/JCP.0b013e3182971e68.

78. Usall J, Lopez-Carrilero R, Iniesta R, et al. Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia. J Clin Psychiatry. 2014 Jun;75(6):608-15. doi: 10.4088/JCP. 13m08551.

79. Kirli S, Caliskan M. A comparative study of sertraline versus imipramine in postpsychotic depressive disorder of schizophrenia. Schizophr Res. 1998 Sep 7;33(1-2):103-11.

80. Lee MS, Kim YK, Lee SK, et al. A doubleblind study of adjunctive sertraline in haloperidol- stabilized patients with chronic schizophrenia. J Clin Psychopharmacol. 1998 Oct;18(5): 399-403.

81. Addington D, Addington J, Patten S, et al. Double-blind, placebo-controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia. J Clin Psychopharmacol. 2002 Feb;22(1):20-5.

82. Mulholland C, Lynch G, King DJ, Cooper SJ. A double-blind, placebo-controlled trial of sertraline for depressive symptoms inpatients with stable, chronic schizophrenia. J Psychopharmacol. 2003 Mar;17(1):107-12.

83. Omranifard V, Hosseini GM, Sharbafchi MR, et al. Sertraline as an add-on treatment for depressive symptoms in stable schizophrenia: a double-blind randomized controlled trial. Journal Research Medical Sciences. 2012;Special Issue(1):1-7.

84. Han PJ, Paik YS, Oh SW, et al. The effect of paroxetine in chronic schizophrenic inpatients with depressive symptoms: a double-blind placebo-controlled study. Journal Korean Neuropsychiatric Association. 2000;39(4):774-86.

85. Jockers-Scherü bl MC, Bauer A, Godemann F, et al. Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics: a double-blind placebo-controlled study. Int Clin Psychopharmacol. 2005 Jan;20(1):27-31.

86. Iancu I, Tschernihovsky E, Bodner E, et al. Escitalopram in the treatment of negative symptoms in patients with chronic schizophrenia: a randomized double-blind placebo-controlled trial. Psychiatry Res. 2010 Aug 30;179(1):19-23. doi: 10.1016/j.psychres.2010.04.035. Epub 2010 May 15.

87. Rusconi AC, Carlone C, Muscillo M, et al. SSRI antidepressants and negative schizophrenic symptoms: differences between paroxetine and fluvoxamine in patients treated with olanzapine. Riv Psichiatr. 2009 Sep- Oct;44(5):313-9.

88. Чайка ЮЮ. Типология и динамика постшизофренических депрессий. Український вiсник психоневрологiї. 1999;7(3):130-4. [Chaika YuYu. Typology and dynamics of postschizophrenic depressions. Ukraїns'kii vіsnik psikhonevrologії. 1999;7(3):130-4. (In Russ.)].

89. Конева ОВ. Постшизофреническая депрессия: клинические, реабилитационные и адаптационные аспекты. Автореф. дисс. канд. мед. наук. Томск; 2009. 23 с. [Koneva OV. Postschizophrenic depression: clinical, rehabilitation and adaptive aspects. Autoref. diss. cand. med. sci. Tomsk; 2009. 23 p.]

90. Будза ВГ, Антохин ЕЮ. Проблема депрессии при шизофрении (обзор – сообщение первое): возможные механизмы. Психиатрия и психофармакотерапия. 2014;16(1):53-62. [Budza VG, Antokhin EYu. The problem of depression in schizophrenia (review - first message): possible mechanisms. Psikhiatriya i psikhofarmakoterapiya. 2014;16(1):53-62. (In Russ.)].

91. Будза ВГ, Антохин ЕЮ. Проблема депрессии при шизофрении (обзор – сообщение второе): типология и течение постшизофренических депрессий. Психиатрия и психофармакотерапия. 2014;16(2):47-53. [Budza VG, Antokhin EYu. The problem of depression in schizophrenia (review – second message): typology and progress of postschizophrenic depressions. Psikhiatriya i psikhofarmakoterapiya. 2014;16(2):47-53. (In Russ.)].

92. Thakore JH, Berti C, Dinan TG. An open trial of adjunctive sertraline in the treatment of chronic schizophrenia. Acta Psychiatr Scand. 1996 Sep;94(3):194-7.

93. Аведисова АС. Подходы к оценке терапии психотропными препаратами. Психиатрия и психофармакотерапия. 2004;6(1):4-6. [Avedisova AS. Approaches to the evaluation of therapy with psychotropic drugs. Psikhiatriya i psikhofarmakoterapiya. 2004;6(1):4-6. (In Russ.)].

94. Agarwal V, Agarwal KM. Treatment of obsessive compulsive symptoms in schizophrenia with fluoxetine. Indian J Psychiatry. 2000 Jul;42(3):291-4.

95. Reznik I, Sirota P. Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics. J Clin Psychopharmacol. 2000 Aug;20(4):410-6.


For citation:


Danilov D.S., Magomedova D.O., Matsneva M.E. The rationale for antidepressants in the treatment of schizophrenia: A modern view on the problem in the context of evidence-based medicine. Neurology, Neuropsychiatry, Psychosomatics. 2016;8(1):71-81. (In Russ.) https://doi.org/10.14412/2074-2711-2016-1-71-81

Views: 935


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)